# Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma

> **NCT05509478** · PHASE2 · UNKNOWN · sponsor: **The First Hospital of Jilin University** · enrollment: 46 (estimated)

## Conditions studied

- Biliary Tract Cancer

## Interventions

- **DRUG:** Lenvatinib
- **DRUG:** PD-1 inhibitors

## Key facts

- **NCT ID:** NCT05509478
- **Lead sponsor:** The First Hospital of Jilin University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-20
- **Primary completion:** 2023-02-01
- **Final completion:** 2023-09-01
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2022-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05509478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05509478, "Lenvatinib Combined With PD-1 Inhibitors as First-line Treatment for Unresectable/Advanced Biliary Tract Carcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05509478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*